CDPPB does not influence spontaneous locomotor activity but attenuates MK-801-induced hyperlocomotion. Animals were injected (s.c./i.p.) with PBS/Vehicle (0/0), 0.2 mg/kg MK-801/Vehicle (0.2/0), 0.2 mg/kg MK-801/3 mg/kg CDPPB (0.2/3) or 0.2 mg/kg MK-801/10 mg/kg CDPPB (0.2/10) 20 minutes before being placed in the activity chamber. Activity was recorded for 30 minutes. Data are expressed as mean ± SEM of distance traveled (n=6-7). **p<0.01 vs. 0.2 mg/kg MK-801/Vehicle group (One-way ANOVA, Bonferroni’s posttest).

CDPPB does not influence spontaneous locomotor activity but attenuates MK-801-induced hyperlocomotion. Animals were injected (s.c./i.p.) with PBS/Vehicle (0/0), 0.2 mg/kg MK-801/Vehicle (0.2/0), 0.2 mg/kg MK-801/3 mg/kg CDPPB (0.2/3) or 0.2 mg/kg MK-801/10 mg/kg CDPPB (0.2/10) 20 minutes before being placed in the activity chamber. Activity was recorded for 30 minutes. Data are expressed as mean ± SEM of distance traveled (n=6-7). **p<0.01 vs. 0.2 mg/kg MK-801/Vehicle group (One-way ANOVA, Bonferroni’s posttest).


Go to product page


Image may be subject to copyright.